COSMO Pharmaceuticals N.V.
A specialty pharmaceutical firm focused on gastroenterology, dermatology, and healthtech.
COPN | SW
Overview
Corporate Details
- ISIN(s):
- NL0011832936
- LEI:
- 724500OX0EBQRYTVV639
- Country:
- Netherlands
- Address:
- Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
- Website:
- https://www.cosmopharma.com/
- Sector:
- Manufacturing
Description
COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-27 02:00 |
Cosmo erhält positive CHMP-Stellungnahme für Winlevi® zur Behandlung von Akne b…
|
German | 8.8 KB | ||
| 2025-08-08 02:00 |
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of O…
|
English | 4.7 KB | ||
| 2025-08-08 02:00 |
Cosmo und Takeda verlängern ihre strategische Produktionsvereinbarung für die w…
|
German | 5.0 KB | ||
| 2025-08-06 02:00 |
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffir…
|
English | 3.3 KB | ||
| 2025-08-06 02:00 |
Cosmo Pharmaceuticals bestätigt, dass keine Auswirkungen durch geplante US-Zöll…
|
German | 4.0 KB | ||
| 2025-07-23 02:00 |
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance …
|
English | 22.3 KB | ||
| 2025-07-23 02:00 |
Cosmo liefert starke Ergebnisse im ersten Halbjahr 2025, erhöht EBITDA-Guidance…
|
German | 24.4 KB | ||
| 2025-07-17 02:00 |
Cosmo announces launch of Winlevi® for Treatment of Acne in Singapore and Malay…
|
English | 9.5 KB | ||
| 2025-07-17 02:00 |
Cosmo: Markteinführung von Winlevi® zur Behandlung von Akne in Singapur und Mal…
|
German | 10.7 KB | ||
| 2025-07-16 02:00 |
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact…
|
English | 6.4 KB | ||
| 2025-07-16 02:00 |
Cosmo baut Vorreiterrolle im Bereich ESG durch bedeutende Rating-Upgrades, die …
|
German | 7.4 KB | ||
| 2025-07-01 02:00 |
Cosmo Unveils Bold 2030 Vision and Strategy; launches AI-driven Growth Phase at…
|
English | 8.4 KB | ||
| 2025-07-01 02:00 |
Cosmo präsentiert mutige Vision und Strategie für 2030 und leitet am Investoren…
|
German | 9.5 KB | ||
| 2025-06-25 02:00 |
Cosmo Announces Sale of “Digital Trust” in Strategic Portfolio Streamlining Move
|
English | 6.8 KB | ||
| 2025-06-25 02:00 |
Cosmo gibt Verkauf von «Digital Trust» im Rahmen einer strategischen Portfolio-…
|
German | 7.4 KB |
Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for COSMO Pharmaceuticals N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
